BiotechTubeBiotechTube
Home/Pipeline/PD1-Vaxx (IMU-201)

PD1-Vaxx (IMU-201)

Non-small cell lung cancer (NSCLC)

Phase 1Active

Key Facts

Indication
Non-small cell lung cancer (NSCLC)
Phase
Phase 1
Status
Active
Company
Imugene

About Imugene

Imugene is focused on developing next-generation immunotherapies that aim to stimulate the body's immune system to fight cancer. Its core technology platforms include oncolytic virotherapy (CF33), B-cell immunotherapy (HER-Vaxx), and checkpoint inhibitor therapies. The company has multiple candidates in clinical development, primarily targeting gastrointestinal cancers and other solid tumors, and operates through strategic collaborations with leading cancer research institutions.

View full company profile

Therapeutic Areas

OncologyImmuno-oncology

Other Non-small cell lung cancer (NSCLC) Drugs

DrugCompanyPhase
NBTXR3 + anti-PD1NanobiotixPhase 1
TTFieldsNovocurePhase 3
Mupadolimab (CPI-006)Corvus PharmaceuticalsPhase 1/2
VAC2Lineage Cell TherapeuticsPhase 1
TG6050Transgene SAPreclinical
Monalizumab (IPH2201)Innate PharmaPhase 3
PlinabulinBeyondSpringPhase 2/3
ATNM-400Actinium PharmaceuticalsPreclinical
Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab)GenprexPhase 1/2
ABD-3001Advanced BiodesignPhase 1